# Resting-state gamma power in schizophrenia: a systematic review and meta-analysis

## TL;DR

This study finds that people with schizophrenia have higher resting-state gamma brain activity, but the effect is small and varies depending on factors like illness duration and medication.

## Contribution

The paper provides the first meta-analysis of resting-state gamma power in schizophrenia, identifying key moderators of effect heterogeneity.

## Key findings

- Whole-brain gamma power is significantly elevated in schizophrenia (g=0.371).
- Frontal and temporal regions show the most consistent increases in gamma activity.
- Illness duration and medication status are significant predictors of gamma power differences.

## Abstract

Gamma-band oscillations, generated by excitatory-inhibitory circuit interactions, are strongly implicated in schizophrenia, yet evidence on resting-state abnormalities remains inconsistent. We conducted a systematic review and meta-analysis of EEG and MEG studies comparing resting-state gamma activity in patients with schizophrenia and healthy controls, following PRISMA guidelines and assessing study quality with the Newcastle-Ottawa Scale. Twenty studies (n = 998 patients; n = 952 controls) were included. Standardized mean differences (Hedges’ g) were calculated and pooled using random-effects models. Results demonstrated a significant elevation of whole-brain gamma power in schizophrenia (g=0.371; 95% CI = 0.119–0.622; P < 0.001; I² = 78.2%). Region-specific analyses showed increases in frontal and temporal cortices, with smaller or inconsistent effects in parietal, occipital, and default mode network (DMN) regions. Meta-regression revealed illness duration (β=1.13) and medication status (β=0.43) as positive predictors, while eyes-open resting conditions attenuated effects (β=−0.70), indicating that both clinical chronicity and methodological factors contribute to heterogeneity. Publication bias was not evident by Egger’s test, although trim-and-fill suggested five potentially missing small-effect studies, reducing the pooled estimate to g=0.130. Sensitivity analyses confirmed that findings were not driven by outliers, and GRADE assessments rated the certainty of evidence as moderate for whole-brain gamma and low for regional outcomes. Taken together, these findings suggest that resting-state gamma power differences in schizophrenia represent a small and heterogeneous group-level effect, shaped by illness duration, medication status, and recording conditions. Rather than indicating a uniform abnormality, the results underscore substantial variability across studies and highlight the need for cautious interpretation. Future large-scale, longitudinal, and multimodal investigations-particularly in unmedicated and first-episode patients-are warranted to clarify the temporal dynamics, causal mechanisms, and potential translational relevance of resting-state gamma activity in schizophrenia.